Daily Newsletter

27 September 2023

Daily Newsletter

27 September 2023

IR-MED plans usability study for PressureSafe device ahead of US launch

The study will assess the usability of the PressureSafe device to detect pressure injuries in people with darker skin tones.

Phalguni Deswal September 27 2023

IR-MED has signed a Clinical Trial Agreement with the Methodist Healthcare System of San Antonio to conduct a usability study of its PressureSafe device in people with different skin tones.

PressureSafe device uses artificial intelligence (AI) to analyse the infrared spectrographic data collected from the device to detect the presence of pressure injuries. In a previous study, the device demonstrated 96% sensitivity and 91% specificity in detecting the presence of a wound.

Usage of generative AI in the medical devices sector has been steadily increasing in the past few years. A GlobalData report forecasted that the AI market will be worth $909bn by 2030.

Pressure injuries are ulcers (sores) which can develop in patients with limited or no mobility who are either bedridden, unconscious, or unable to sense pain. The current standard for diagnosing pressure injuries is a visual examination, but this can be harder to do in people with darker skin tones. A study estimates that about 1-3 million people have pressure injuries in the US, with 5-15% of patients in long-term intensive care suffering from these ulcers.

The new study will build upon the existing knowledge and test the device in people with darker skin tones. The trial will aim to enrol half of the patient population with darker skin tones to provide a comparison analysis of the PressureSafe device's accuracy in detecting early-stage pressure injuries in people of darker and lighter skin tones.

IR-MED plans to file for the US Food and Drug Administration (FDA) approval in the last quarter of 2023, and intends to launch the device in the first half of 2024.

Similar devices in the field include MolecuLight’s fluorescence imaging device, MolecuLight i:X, which can be used to identify the presence of bacteria in wounds. A device study showed that using the device boosted the 12-week healing rates by 204% in patients with diabetic foot ulcers.

Sky Medical Technology’s self-adhesive, wearable ‘geko’ device also promotes wound healing by delivering an electrical pulse to stimulate blood flow. It received a marketing clearance from the US FDA to improve blood flow in the ischaemic tissue of the leg in 2021.

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close